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Abstract 
Hepatocyte death is an important contributing factor in a number of diseases of the liver. PHD1 
confers hypoxic sensitivity upon transcription factors including the hypoxia inducible factor (HIF) and 
nuclear factor-kappaB (NF-κB). Reduced PHD1 activity is linked to decreased apoptosis. Here, we 
investigated the underlying mechanism(s) in hepatocytes. Basal NF-κB activity was elevated in PHD1-
/- hepatocytes compared to wild type controls. ChIP-seq analysis confirmed enhanced binding of NF-
κB to chromatin in regions proximal to the promoters of genes involved in the regulation of apoptosis. 
Inhibition of NF-κB (but not knock-out of HIF-1 or HIF-2) reversed the anti-apoptotic effects of 
pharmacologic hydroxylase inhibition. We hypothesize that PHD1 inhibition leads to altered 
expression of NF-κB-dependent genes resulting in reduced apoptosis. This study provides new 
information relating to the possible mechanism of therapeutic action of hydroxylase inhibitors that has 
been reported in pre-clinical models of intestinal and hepatic disease. 
 
Keywords: prolyl hydroxylase, NF-κB, apoptosis, hypoxia. 
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Introduction 
The chemical reduction of molecular oxygen is central to eukaryotic metabolism. Hypoxia 
therefore represents a significant threat to bioenergetic homeostasis and cell survival. 
Eukaryotic cells evolved an adaptive transcriptional response to hypoxia which is mediated 
primarily by the hypoxia inducible factor (HIF) [1]. The enzymes responsible for conferring 
hypoxic sensitivity upon HIF are termed prolyl hydroxylases (PHDs) [1]. 
A second key hypoxia-sensitive transcription factor is NF-kappaB (NF-κB). In unstimulated 
cells, NF-κB is retained in the cytoplasm by IkappaB (IκB) proteins [2]. Upon stimulation of 
cells by pro-inflammatory signals, IκB is phosphorylated by IκB kinase (IKK) targeting it for 
proteasomal degradation. Liberated NF-κB dimers then translocate to the nucleus and regulate 
transcription of a range of genes including a number associated with the regulation of 
apoptosis [3]. Hypoxia regulates NF-κB activity in a hydroxylase-dependent manner although 
this is a complex relationship. In the basal state, hydroxylase inhibition induces a low level 
activation of NF-κB, whereas in cells stimulated with Interleukin-1beta (IL-1β), hydroxylase 
inhibition suppresses NF-κB [4, 5]. 
Pharmacologic hydroxylase inhibition is protective in a number of models of intestinal 
inflammation [6-13]. Based on experiments utilizing isoform-specific PHD knock-out mice, it 
was shown that knock-out of PHD1 (but not PHD2 or PHD3) is responsible for protection 
against the development of colitis through inhibition of apoptosis in epithelial cells and 
consequent improvement in intestinal barrier function [14]. Hepatocytes also express 
functional PHD1 and PHD1 knock-out mice are protected against liver ischemia/reperfusion 
injury in a manner which is associated with reduced hepatocyte apoptosis [15]. However, the 
molecular mechanisms linking PHD-1 activity and apoptosis remain unclear and are the topic 
of this study.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
Materials and Methods 
 
Reagents. All chemicals were obtained from Sigma Aldrich except DMOG (Cayman 
Chemicals). FLAG-EGLN2 was from William Kaelin (Harvard Medical School). FLAG-
IKKβ was from Warner Greene (Addgene plasmid #23298) [16]. HIF HepG2 cells were from 
Bernhard Brüne (University of Frankfurt). 
 
Cell culture. Primary hepatocytes, derived from wild type or PHD1-/- Swiss/129 mice, Caco-
2, HepG2 and HEK293 cells were cultured using standard conditions.  
 
Site directed mutagenesis. The P191A-IKKβ mutant was generated using QuikChange 
Lightning mutagenesis kit (Agilent Technologies). Forward and reverse primers for IKKβ 
were 5’- CCCTGC AGTACCTGGCCGCAGAGCTACTGGAGC-3’ and 5’- 
GCTCCAGTAGCTCTGCGGCCA GGTACTGCAGGG-3’, respectively. 
 
Transient transfections. HEK293 cells were transfected using 1 µg DNA in 1 µL/mL 
Lipofectamine 2000 (Life Technologies). HepG2 cells were transfected with siRNA (ON-
Target Plus #L-004277-00-0010 and #D-001810-01-05, Dharmacon) using 5 µL/mL Trans-IT 
X2 (Mirus Bio LLC, Medison, WI, USA) in culture medium. 
 
Immunhistochemistry. 4 µM sections of tissue were cut from paraffin blocks, deparaffinised 
and rehydrated using standard protocols. Sections were treated with proteinase K (20 µg/mL 
in 10mmol/L Tris-HCl, pH 7.5) for 15 minutes at RT before quenched with 3% hydrogen 
peroxide solution for 10 minutes, blocked using 5% normal goat serum in PBS containing 
0.1% Triton X-100 (PBST) for 1 hour at RT and incubated with a primary anti-PHD1 
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antibody (Epitomics, Burlingame, CA) in 2% goat serum in PBST at 4 °C overnight. Slides 
were stained with a biotinylated goat anti-rabbit antibody (Vector Laboratories, Peterborough, 
UK) and developed using 3,3’-diaminobenzidine. Images were acquired using an Aperio 
Scanscope XT digital slide scanner. 
 
In vitro transcription/translation. A rabbit reticulocyte-based transcription/translation 
system was used as per manufacturer’s instructions (Promega) using cDNA of FLAG-tagged 
PHD-1 cloned into pcDNA3 vector or the empty vector alone as template as indicated. 
 
Mass spectrometry. N-terminally biotinylated synthetic peptides of 
GSLATSFVGTLQYLAPELLEQQKY (GL Biochem, Shanghai) were incubated with the 
complete reaction mixture from the in vitro transcription/translation assay as described 
previously [17]. Peptides were then isolated using monovalent streptavidin resin (Amersham), 
eluted, desalted and subjected to reverse-phase liquid chromatography coupled to mass 
spectrometry (LC-MS/MS) as described in [5]. The IKKβ peptide containing the Proline 191 
residue was quantified by comparing the XIC of the threefold charged modified peptide and 
unmodified peptides using a window of 0.02 Da. Normalization of hydroxylated peptide was 
performed by dividing the intensity of the modified peptide by the matching unmodified 
peptide. 
 
In vitro decarboxylation assay. The assay was performed as described previously [18]. 
 
Chromatin immunoprecipitation sequencing (ChIP-Seq). Libraries were prepared from 
immunoprecipitated chromatin and sequence analysis was performed on an Illumina HiSeq 
2000 (GATC-Biotech AG, Konstanz, Germany). Sequences were mapped to NCBI mouse 
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genome (mm9). Reads were aligned with BWA aligner [19]. For peak calling, FindPeaks 
version 4.0 was used with standard parameters for control/case with a p-value cut-off of 0.01 
[20]. The overlaps of the peaks were analysed using the R/bioconductor package 
ChIPpeakAnno [21, 22]. When computing the overlaps between different subunits, the 
maximum gap allowed between the peaks was 100 base pairs. For the same subunit no gap 
was permitted. Raw data can be sourced using the following URLs for (1) p50 binding in 
PHD1-/- cells, (2) p50 binding in WT cells, (3) p65 binding in PHD1-/- cells and (4) p65 
binding in WT cells respectively: 
1) http://titin.ucd.ie/~tom/susan/p50.allsample.bed 
2) http://titin.ucd.ie/~tom/susan/p50.allcontrol.bed 
3) http://titin.ucd.ie/~tom/susan/p65.allsample.bed 
4) http://titin.ucd.ie/~tom/susan/p65.allcontrol.bed 
Corresponding peak height information can be found at: 
1) http://titin.ucd.ie/~tom/susan/p50.allcontrol.peaks 
2) http://titin.ucd.ie/~tom/susan/p50.allsample.peaks 
3) http://titin.ucd.ie/~tom/susan/p65.allcontrol.peaks 
4) http://titin.ucd.ie/~tom/susan/p65.allsample.peaks 
 
Real-time quantitative PCR. Total RNA was isolated, analysed and transcribed into cDNA 
as described in [23]. PCR reaction was performed using the apoptosis specific human 
TaqMan Array Microfluidic Card #4378716 and ABI Prism 7900HT Sequence Detection 
System according to manufacturer instructions (Applied Biosystems). Expression levels were 
calculated by the delta delta Ct (∆∆Ct) method using β-Actin as selected endogenous control. 
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Immunobloting. Analyses were carried out as detailed previously [24]. Primary antibodies 
used are summarized in Table 1. 
 
NF-κB luciferase reporter assay. Luciferase reporter assays were carried out as described 
previously [4, 5]. 
 
Flow Cytometry. HepG2 cells were incubated with YO-PRO-1® and propidium iodide 
(Membrane Permeability/Dead Cell Apoptosis Kit, Invitrogen (Thermo Fisher Scientific, 
Waltham, MA USA) and subjected to flow cytometric analysis using the BD Accuri C6 flow 
cytometer (BD Bioscience, Oxford, UK) and CFlow software (version 1.0.264.21). 15000 
cells were analyzed per sample and a minimum of three replicates per experiments were 
performed. 
 
Statistical Analysis Data are presented as mean±SEM for n≥3 independent experiments. 
Statistical significance was evaluated by using one-way ANOVA or Student’s t test for 
unpaired or paired data, respectively. Asterisks correspond to P≤0.05. 
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Results 
NF-κB activity is elevated in PHD1-/- hepatocytes 
Immunohistochemical analysis of liver sections from wild type (WT) and PHD1-/- mice 
revealed nuclear enrichment of phosphorylated p50 in tissue from PHD1-/- mice compared to 
WT suggesting that PHD1 depletion leads to the activation of NF-κB in hepatocytes (Figure 
1A). A potential target for PHD-dependent hydroxylation in the NF-κB pathway is IKKβ as it 
contains an LxxLAP hydroxylation motif similar to those found in HIFα subunits between 
amino acids 186 and 191 [4, 18]. This suggests that proline 191 (Pro191) could be a target for 
functional hydroxylation [4]. Rabbit reticulocyte-translated PHD1 was incubated with a 
synthetic peptide containing the putative hydroxylation motif of IKKβ. Mass spectrometric 
analysis revealed increased levels of proline hydroxylated peptide in the samples incubated 
with PHD1-reticulocyte lysates compared to those incubated with control lysates (Figure 1B). 
While peptides incubated in control lysates were predominantly in the non-hydroxylated state 
(Figure 1C), peptides incubated with lysates containing PHD1 showed two fractions of 
comparable abundance (Figure 1D). One of these fractions was identified as peptide 
hydroxylated on the proline residue corresponding to Pro191 of IKKβ.  Mass spectrometric 
analysis also revealed that incubation with reticulocyte lysate resulted in the oxidation of the 
N-terminal affinity label biotin. In the presence of PHD1 we additionally detected the 
hydroxylation of Pro191.  (Figure 1B,D). 
These in vitro data support the possibility that Pro191 of IKKβ is a target for hydroxylation 
by PHD1. It is noteworthy that Pro191 hydroxylation was detected in samples incubated in 
the absence of PHD1 (Figure 1B) suggesting either that this site is prone to non-enzymatic 
oxidation or modified by other hydroxylases in the rabbit reticulocyte lysate.  
To investigate whether PHD1 alone is sufficient to catalyze IKKβ hydroxylation, we next 
incubated IKKβ peptides with purified PHD1 in a cell-free reaction mixture and performed a 
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decarboxylation assay. Purified full length HIF-1α was used as a positive control substrate for 
PHD1. In contrast to the experiment in which peptides were incubated with whole 
reticulocyte lysates, peptide hydroxylation was not consistently detected in the lysate-free 
hydroxylation assay (Figure 1F). This may reflect the requirement for additional co-factors 
(present in the reticulocyte lysate) which are required for the PHD1-mediated IKKβ 
hydroxylation but not for HIF-1α hydroxylation. While identifying such factor(s) is beyond 
the scope of the current manuscript, future studies will be directed towards investigating this 
important question. 
We next investigated a possible functional role for Pro191 in NF-κB signaling. We generated 
a P191A IKKβ mutant and compared its NF-κB activating potential to WT IKKβ. 
Overexpression of WT IKKβ reduced basal levels of IκBα and increased p65 phosphorylation 
on serine 536 indicating enhanced NF-κB signaling (Figure 2Α) [25]. In cells stimulated with 
TNFα, IκBα degradation and Ser536 phosphorylation of p65 were increased further when 
WT IKKβ is overexpressed (Figure 2A and 2B). In contrast, the P191A IKKβ failed to exert 
similar effects on NF-κB pathway (Figure 2A and 2B). Overexpression of WT IKKβ also 
resulted in robustly elevated basal NF-κB activity (as measured by luciferase reporter assay) 
compared to mock-transfected cells and this activation was refractive to further stimulation by 
TNFα  while the P191A mutant failed to increase basal NF-κB activity and rendered cells 
unresponsive to TNFα stimulation (Figure 2C). These data support the hypothesis that proline 
191 of IKKβ is important for the catalytic activity of the kinase. Thus, its PHD1-mediated 
hydroxylation may affect its critical role in the signal transduction of the canonical NF-κB 
pathway. 
 
PHD1 knockout changes the DNA binding pattern of NF-κB in primary hepatocytes 
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We next employed chromatin immunoprecipitation combined with DNA sequencing (ChIP-
seq) to determine the distribution of binding sites of the p50 and p65 subunits of NF-κB 
throughout the genome. We found elevated numbers of binding sites for both p50 and p65 in 
chromatin from primary hepatocytes derived from PHD1-/- mice compared to WT controls 
(Figure 3A). We identified 3445 and 6945 unique binding sites for p50 and p65, respectively, 
in PHD1-/- cells compared with 61 and 584 unique binding sites for p50 and p65, respectively, 
in WT cells. The average relative distances of these binding sites from the nearest 
transcription factor start site was not significantly different between the wild type and the 
PHD1-/- (Figure 3B). Further analysis identified differential NF-κB binding to chromatin close 
to a cohort of genes known to be involved in the regulation of apoptosis (Figure 3C-H). In 
some cases, e.g. TRAIL, different peak heights were observed between WT and PHD1-/- cells, 
indicative of the differential degree of binding. In other cases (e.g. CASPASE-3, CASPASE-6, 
BIRC2, BIRC4 and FADD) unique binding sites were identified in PHD1-/- cells. It is 
noteworthy, that unique binding sites for p50 were frequently found in genes considered to be 
pro-apoptotic whereas p65 was more often enriched proximal to anti-apoptotic genes (Figure 
3C-H).  
In order to take an alternative approach to investigating the role of PHD1 in regulating 
apoptotic gene expression, we next carried out a quantitative PCR-based screening array of a 
panel of apoptosis-related genes. Using this approach, we identified a cohort of pro-apoptotic 
genes that are downregulated in HepG2 cells in which PHD1 was knocked down using siRNA 
compared to mock transfected controls (Table 1). These included critical elements of the 
intrinsic apoptotic pathway e.g. APAF1, DIABLO or PUMA. Interestingly, a number of 
caspase encoding genes were also found to be down-regulated as well as elements of the NF-
κB pathway itself including the IKKγ and ε subunits, the β and ζ isoforms of the IκB and the 
TNF-related apoptosis inducing ligand (TRAIL) receptor 1 and 2. These data indicate the 
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genome-wide relocation of p50 and p65 in response to inhibition of PHD1 results in 
differential expression of genes involved in the regulation of apoptosis. Overall, these 
findings suggest that gene expression is biased toward an anti-apoptotic / pro-survival state 
upon the inhibition of PHD1 in hepatocytes. 
 
Pharmacological PHD inhibition promotes hepatocyte survival. 
To test whether hydroxylase inhibition protects hepatocytes by reducing the rate of apoptosis 
in an NF-κB-dependent manner, we exposed HepG2 cells to TRAIL in the presence or 
absence of the hydroxylase inhibitor DMOG and Bay-117082 which inhibits TNFα-induced 
NF-κB activity in HepG2 cells (Figure 4A) [26]. TRAIL profoundly increased apoptosis in a 
manner that was partially reversed by DMOG treatment. The protective effects of DMOG 
were reversed by Bay-117082 indicating that NF-κB signaling mediates the anti-apoptotic 
effect of hydroxylase inhibitors in hepatocytes (Figure 4B and 4C). To investigate whether 
there was also a role for HIF1 or HIF2, we investigated whether the anti-apoptotic effect of 
DMOG is lost in HIF-/- cells. RNA interference-mediated knock-down of either HIF-1 or HIF-
2α (Figure 4D) had no significant impact on the anti-apoptotic effects of DMOG (Figure 4E 
and 4F). These data indicate that the anti-apoptotic effects of the hydroxylase inhibition are 
independent of the HIF pathway and due instead to the activation of NF-κB. 
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Discussion 
Recent work has shown that protein hydroxylation is not restricted to HIFα subunits and that 
components of other pathways such as NF-κB may also be functional targets for hydroxylases 
[4, 5, 27-29]. Consistent with these studies, we identified a global increase in NF-κB binding 
to chromatin in PHD1-/- hepatocytes.  This may explain the observed anti-apoptotic effects of 
hydroxylase inhibition. 
Protective effects of PHD1 knockout, due to decreased apoptosis, have been reported in 
models of colitis and liver ischemia/reperfusion injury [14, 15]. Furthermore, PHD1-/- mice 
display decreased cardiomyocyte apoptosis and are protected against ischemia reperfusion 
injury [15, 28, 30]. However, the molecular mechanisms underpinning the link between 
hydroxylase inhibition and apoptosis is unclear. 
In this manuscript, we propose a model whereby PHD1 promotes apoptosis by suppressing 
NF-κB activity. PHD1 inhibition prevents apoptosis by increasing the activity of IKKβ 
leading to phosphorylation and degradation of IκB with a resultant increase in NF-κB which 
upregulates anti-apoptotic genes. Although our data indicate that the IKKβ may be a bona fide 
target for PHD1, whether this occurs in vivo and is regulated by hypoxia remains to be 
determined [4, 18]. 
The dominant-negative behaviour of the P191A mutant supports the concept that Pro191 is 
important for the catalytic activity of IKKβ. It was previously demonstrated that the intact C-
terminal IKK complex-related phosphor-acceptor site of p105 is a prerequisite for the TNFα-
responsive degradation of p105 and the consequent formation of the p50-containing trans-
activator NF-κB complexes [31]. Since Pro191 is located in the close proximity of the kinase 
regulatory loop of IKKβ, PHD1-mediated hydroxylation of Pro191 on IKKβ may determine 
the composition of NF-κB dimers generated and, consequently, the functional outcome of the 
activation of the pathway. This raises the question of whether hydroxylation of Pro191 
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represents a molecular switch directing altered NF-κB-dependent biological responses upon 
hypoxia. 
Although these mechanistic questions need further investigation, we hypothesize that the 
PHD1-mediated regulation of the NF-κB pathway promotes anti-apoptotic processes that 
underpins part of the protective effects of hydroxylase inhibition in a range of inflammatory 
and ischemic diseases. In intestinal epithelial cells, this may result in an enhancement of the 
barrier function reflected by protection against the initiation and development of colitis while 
in hepatocytes it may contribute to the observed resistance to various pro-apoptotic stimuli. 
Our current data provide additional mechanistic insight into the potential therapeutic 
usefulness of hydroxylase inhibitors. 
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Figure legends 
 
Figure 1. Hydroxylase inhibition activates NF-κB. (A) Immunohistological staining of 
phospho-p50 in liver sections from wild type (WT) and PHD1-/- mice. Representative images 
from 4 animals. (B-E) Mass spectrometric analysis reflecting hydroxylation of a synthetic 
peptide corresponding to the putative hydroxylation site of IKKβ following exposure to either 
control or PHD1-translated rabbit reticulocyte lysates. (F) Cell-free decarboxylation assay 
using synthetic IKKβ peptides or full length HIF-1α and purified PHD1. 
 
Figure 2. Pro191 mutation diminishes IKKβ-dependent NF-κB activity. (A) Cells were 
transfected with empty vector, WT IKKβ or P191A IKKβ, stimulated with TNFα (0-30 mins) 
and markers of NF-κB activity were assessed by western blot. Representative blots of 3 
independent experiments are shown. (B) Normalized densitometry results of quantitative p65 
phosphorylation. (C) Normalized basal and TNFα-induced NF-κB-luciferase reporter activity 
in cells transfected with empty vector, WT IKKβ or P191A IKKβ (n=3). 
 
Figure 3. PHD1 removal alters the DNA-binding pattern of NF-κB in hepatic tissues. (A) 
A Venn diagrams displaying the numbers of unique and shared p50 (upper panel) and p65 
(lower panel) binding sites in hepatocytes derived from wild type and PHD1-/- mice. (B) 
Diagrammatic representation of distances of p50 and p65 binding sites from nearest known 
transcriptional start site (TSS) in hepatocytes derived from wild type (WT) and PHD1-/- mice. 
(C-H) The number of binding sites (represented by the individual bars in the histograms) and 
the peak height data (represented by the height of the bars) for p50 (left hand side) and p65 
(right hand side) were compared between wild type (white bars) and PHD1-/- (black bars) 
hepatocytes for apoptosis-related genes as indicated in the figure.  
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Figure 4. Inhibition of PHD1 promotes hepatocyte survival. (A) NF-κB luciferase reporter 
activity in hepatocytes treated with TNFα (1 ng/ml) +/- Bay 11-7082 (10µM). Assessment of 
live (B) and apoptotic (C) cells treated with TRAIL, DMOG and Bay117802. (D) Knock-
down of HIF1α and HIF2α protein in HepG2 cells. A representative immunoblot of n=3 
independent experiments is shown. (E-F) HepG2 cells lacking either HIF1α or HIF2α were 
exposed to TRAIL (100ng/ml) and cycloheximide (CHX, 1µg/ml) for 3 hours following 
DMOG pre-treatment (1mM, 24h). The percentage of live (E) and apoptotic (F) cells were 
assessed by flow cytometry. Data represent mean ± SEM of 3 (A) or 4 (B and C) independent 
experiments (* p< 0.05, **p< 0.01, ***p> 0.0001, two way ANOVA, Bonferroni post-test for 
A, one way ANOVA, Tukey post-test for B, C, D and E).  
 
Table 1. Summary of details of antibodies used in the study. 
 
Table 2.  
Summary of down-regulated apoptotic genes in PHD1-/- HepG2 cells (shown as mean fold 
change compared to cells transfected with non-targeting siRNA (n=4 independent 
experiments). 
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Table 1. 
 
 
 
 
 
 
 
 
 
 
 
Table 2. 
 
Gene ID Mean expression SD Gene ID Mean expression SD 
APAF1 0.633275 0.073525 Caspase-10 0.652075 0.054038 
PUMA 0.617925 0.039463 CFLAR 0.61035 0.027075 
BCL2-like 10 0.5988 0.04365 Diablo 0.613825 0.041975 
BCL2-like 11 0.688625 0.100525 HIP-1 0.66035 0.08605 
BCL-W 0.66415 0.07535 IKK-ε 0.669425 0.091975 
BIK 0.542175 0.041713 IKK-γ 0.626275 0.091225 
BIRC5 0.667825 0.039125 IκBβ 0.65525 0.0438 
BIRC6 0.65565 0.05475 IκBζ 0.665875 0.073425 
BOK 0.698125 0.056375 PEA15 0.675 0.0703 
Caspase-5 0.5988 0.04365 PYCARD 0.5225 0.0699 
Caspase-6 0.6823 0.07655 TNFRSF10A 0.647525 0.093075 
Caspase-7 0.5593 0.03355 TNFRSF10B 0.681025 0.093025 
 
Antibody Host Manufacturer Cat. # 
Anti-FLAG Mouse Sigma Aldrich F1804 
Anti-IKKβ Goat Santa Cruz sc-7329 
Anti-phospho IKKβ Rabbit Cell Signaling 2694S 
Anti-IκBα Mouse Cell Signaling 4814S 
Anti-phospho IκBα (Ser32) Rabbit Cell Signaling 2859S 
Anti-p65 Mouse Cell Signaling 6956S 
Anti-phospho p65 (Ser 536) Rabbit Cell Signaling 3033S 
Anti-Nucleolin Mouse Amotif 39541 
Anti-HIF-1α Mouse BD Pharmingen 610958 
Anti-HIF-2α Rabbit Novus  NB100-122 
Anti-β-Actin Mouse Sigma Aldrich A2228 
Anti-Lamin Rabbit Abcam ab16048 
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Highlights 
 
• Genetic ablation of PHD1 upregulates NF-kappaB (NF-κB) in hepatocytes 
• PHD1 blockade-mediated activation of NF-κB leads to differential DNA-binding of p50 and p65 
and result in differential regulation of apoptotic genes 
• We identified proline 191 in the beta subunit of the I-kappaB kinase as a target for PHD1-mediated 
hydroxylation. 
• Blockade of prolyl-4-hydroxylases has been found cytoprotective in liver cells 
 
